Annual Financial Report

RNS Number : 6481Z
Dechra Pharmaceuticals PLC
22 September 2020
 

 

 

22 September 2020

 

 

Dechra® Pharmaceuticals PLC

(the Company)

Annual Financial Report

 

 

The Company announced its Preliminary Results on 7 September 2020 in accordance with the financial reporting obligations of the Disclosure and Transparency Rules.

 

Copies of the Annual Report and Accounts for the year ended 30 June 2020, Notice of Annual General Meeting and Proxy Form have now been mailed to shareholders.

 

In accordance with Listing Rule 9.6.1 a copy of the Annual Financial Report and Notice of Meeting has been submitted to the FCA document viewing facility https://data.fca.org.uk/#/nsm/nationalstoragemechanism .

 

The Annual Report and Accounts, Notice of Annual General Meeting and information relating to the voting rights of Shareholders (as required by section 311A of the Companies Act 2006) are available to view on the Company's website www.dechra.com .  Further copies of the Annual Report and Accounts are available from the Company's registered office at:

 

24 Cheshire Avenue

Cheshire Business Park

Lostock Gralam

Northwich

CW9 7UA

 

 

Enquiries:

Melanie Hall, Company Secretary

Dechra Pharmaceuticals PLC

Tel: +44 (0) 1606 814730

 

 

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

 

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSEANNFAEPEEFA
UK 100

Latest directors dealings